STK3 and sarcoma: Approximately 49% of sarcomas (73/148) demonstrate loss of MST1, 31% of sarcomas (46/148) demonstrate loss of MST2, 23% of sarcomas (34/148) demonstrate loss of LATS1 expression, and 29% of sarcomas (45/153) demonstrate loss of LATS2 (Supplementary Figure 1C).